aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54

aTyr Pharma, Inc. (NASDAQ:LIFE)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.54 and traded as high as $1.70. aTyr Pharma shares last traded at $1.61, with a volume of 359,600 shares trading hands.

Analyst Ratings Changes

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research note on Friday, March 15th. Royal Bank of Canada dropped their target price on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $23.67.

aTyr Pharma Stock Performance

The stock’s fifty day simple moving average is $1.85 and its two-hundred day simple moving average is $1.54. The company has a market cap of $110.06 million, a price-to-earnings ratio of -1.66 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.27 and a current ratio of 6.27.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Equities research analysts anticipate that aTyr Pharma, Inc. will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LIFE. Jane Street Group LLC purchased a new position in shares of aTyr Pharma in the 2nd quarter valued at $29,000. Two Sigma Securities LLC purchased a new stake in shares of aTyr Pharma in the second quarter worth about $26,000. Squarepoint Ops LLC acquired a new stake in shares of aTyr Pharma in the first quarter valued at about $26,000. Virtu Financial LLC acquired a new stake in shares of aTyr Pharma in the first quarter valued at about $70,000. Finally, Granite Bay Wealth Management LLC purchased a new stake in shares of aTyr Pharma during the 4th quarter valued at about $25,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.